Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Anacor Pharmaceuticals (UNKNOWN:ANAC.DL) has received the dreaded one-star ranking.

With that in mind, let's take a closer look at Anacor and see what CAPS investors are saying about the stock right now.

Anacor facts

Headquarters (founded)

Palo Alto, Calif. (2000)

Market Cap

$422.6 million



Trailing-12-Month Revenue

$10.9 million


CEO David Perry (since 2002)
CFO Geoffrey Parker (since 2010)

Return on Capital (average, past 3 years)



$45.8 million / $27.7 million


Johnson & Johnson

Sources: S&P Capital IQ and Motley Fool CAPS.

Just yesterday, All-Star zzlangerhans touched on Anacor's seemingly unsustainable valuation:

[T]avaborole is likely to be an also-ran to Valeant'sĀ efinaconazole which has a substantially higher cure rate in phase III trials. Tavabarole is likely to be approved, but revenues will almost certainly be disappointing. A similar fate may await atopic dermatitis drug AN2728, which is yet to begin phase III trials but was only modestly efficacious in phase II.

As always, when a stock runs like this and attracts pumpers and momo traders I have no idea where the upward trajectory will end. Good chance I go deep into the red here, but a better chance I come out green in the end.